Skip to main content
Top
Published in: Diabetologia 9/2013

01-09-2013 | Letter

The vitamin K-dependent Gla proteins and risk of type 2 diabetes

Authors: R. L. Kennedy, V. Vangaveti, U. H. Malabu, D. McCulloch

Published in: Diabetologia | Issue 9/2013

Login to get access

Excerpt

To the Editor: Recently, Haase et al [1] reported that maternal low-protein diet in rats was associated with decreased beta cell mass and decreased expression of growth arrest specific protein 6 (GAS6) in islets of Langerhans, and that incubation of neonatal islets with GAS6 enhanced beta cell proliferation. Low beta cell mass early in life is associated with increased future risk of type 2 diabetes. Consistent with a protective effect of GAS6, the c.834 + 7G>A polymorphism is associated with type 2 diabetes risk in humans [2]. The AA phenotype is associated with higher levels of GAS6, lower glucose levels, and decreased diabetes risk. Currently used drugs affecting the incretin axis have stimulated interest in therapeutic approaches that either preserve or enhance beta cell mass or function, and GAS6 (secreted by alpha cells) is, therefore, an attractive therapeutic target. …
Literature
1.
go back to reference Haase TN, Rasmussen M, Jaksch CA et al (2013) Growth arrest specific protein (GAS) 6: a role in the regulation of proliferation and functional capacity of the perinatal rat beta cell. Diabetologia 56:763–773PubMedCrossRef Haase TN, Rasmussen M, Jaksch CA et al (2013) Growth arrest specific protein (GAS) 6: a role in the regulation of proliferation and functional capacity of the perinatal rat beta cell. Diabetologia 56:763–773PubMedCrossRef
2.
go back to reference Lee CH, Chu NF, Shieh YS, Hung YJ (2012) The growth arrest-specific 6 (Gas6) gene polymorphism c.834 + 7G>A is associated with type 2 diabetes. Diabetes Res Clin Pract 95:201–206PubMedCrossRef Lee CH, Chu NF, Shieh YS, Hung YJ (2012) The growth arrest-specific 6 (Gas6) gene polymorphism c.834 + 7G>A is associated with type 2 diabetes. Diabetes Res Clin Pract 95:201–206PubMedCrossRef
3.
go back to reference Hsiao FC, Lin YF, Hsieh PS et al (2013) Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents. J Clin Endocrinol Metab 98:E267–E274PubMedCrossRef Hsiao FC, Lin YF, Hsieh PS et al (2013) Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents. J Clin Endocrinol Metab 98:E267–E274PubMedCrossRef
4.
go back to reference Bao Y, Ma X, Yang R et al (2013) Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab 98:345–351PubMedCrossRef Bao Y, Ma X, Yang R et al (2013) Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab 98:345–351PubMedCrossRef
5.
go back to reference Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J (2013) Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 12:22PubMedCrossRef Sheng L, Cao W, Cha B, Chen Z, Wang F, Liu J (2013) Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 12:22PubMedCrossRef
6.
go back to reference Mizokami A, Yasutake Y, Gao J et al (2013) Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One 8:e57375PubMedCrossRef Mizokami A, Yasutake Y, Gao J et al (2013) Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One 8:e57375PubMedCrossRef
7.
go back to reference Polgreen LE, Jacobs DR Jr, Nathan BM, Steinberger J, Moran A, Sinaiko AR (2012) Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity 20:2194–2201PubMedCrossRef Polgreen LE, Jacobs DR Jr, Nathan BM, Steinberger J, Moran A, Sinaiko AR (2012) Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity 20:2194–2201PubMedCrossRef
8.
go back to reference Juanola-Falgarona M, Salas-Salvado J, Estruch R et al (2013) Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol 12:7PubMedCrossRef Juanola-Falgarona M, Salas-Salvado J, Estruch R et al (2013) Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol 12:7PubMedCrossRef
Metadata
Title
The vitamin K-dependent Gla proteins and risk of type 2 diabetes
Authors
R. L. Kennedy
V. Vangaveti
U. H. Malabu
D. McCulloch
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2963-4

Other articles of this Issue 9/2013

Diabetologia 9/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine